Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Turkey Company Roundup: Biosimilar Pact, Keytruda Supply, Takeda Deal

This article was originally published in PharmAsia News

Executive Summary

TUBITAK (The Scientific and Technological Research Council of Turkey) will produce biosimilars with Nobel Ilac, MSD provides pembrolizumab free to 25 patients in Turkey, Abdi Ibrahim intensifies its R&D efforts, and Takeda purchases a portfolio of new products.

You may also be interested in...



Turkish Health System Slides Into Crisis After Devaluation Of Lira

Amid delays in surgical operations caused by shortages of equipment and medtech companies demanding payment of outstanding hospital debts, a strong devaluation of the Turkish lira has put the local health care system on a crisis footing.

Health Care Policy Failings Are Eroding Medtechs’ Confidence In The Turkish Market

Late payment of hospital debts continues to haunt the Turkish medtech industry, which recently led a public demonstration in Ankara to focus the government’s attention on the issue. Medtech multinationals fear that the ongoing problems will mean Turkey losing the positive momentum it achieved during the pandemic.

One Hurdle After Another: Safely Aligned With EU MDR, Turkish Medtechs Brace For New Efforts On Domestic Front

Alignment with the MDR gave Turkish medtech access to the EU market, but in domestic pricing, costs, reimbursement and payment of hospital debts, industry might feel it is barely at the starting line.

Topics

Related Companies

UsernamePublicRestriction

Register

SC088957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel